MAPT and supranuclear palsy, progressive, 1: Additionally, cerebrospinal fluid biomarkers, such as elevated levels of phosphorylated Tau and decreased β-amyloid 42, have proven useful in differentiating PSP from Alzheimer’s disease [58].